The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
some of the mutations in Parkinson's disease have to do with one of the mitochondrial respiratory electron transport chain complexes and by using ketones as fuel we can bypass that so beta-hydroxybutyrate ketones appear to be uniquely beneficial in Parkinson's disease and mitochondrial diseases because they allow the body to deliver electrons to the electron transport chain in the mitochondrial membrane in a different way that can bypass mutations in that chain
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.